Fig. 3.
Treatment of human coronary arterial endothelial cells (HCAECs) with growth hormone (GH) and IGF-I (for 24 h) attenuates cellular reactive oxygen species (ROS) production. A–C: representative fluorescent images showing GH- and IGF-I-treated HCAECs [left: phase contrast image; center: red fluorescent EB staining; right: green H2DCFDA (DCF) fluorescence]. D–G: bar graphs are summary data of EB (D and F) and DCF (E and G) fluorescent intensities in GH- and IGF-I treated HCAECs (D and E) and neonatal rat cardiac myocytes (F and G). Data are means ± SE. *P < 0.05.